What is the antibiotic susceptibility profile of Finegoldia magna?

Antibiotic Susceptibility Profile of Finegoldia magna

Finegoldia magna demonstrates excellent susceptibility to penicillins (benzylpenicillin, amoxicillin-clavulanate), metronidazole, cefoxitin, linezolid, and chloramphenicol, with resistance rates below 4% for penicillins and essentially zero for metronidazole, making these the preferred first-line agents without requiring susceptibility testing. 1, 2

Core Susceptibility Patterns

The most robust recent data from 2022-2023 establishes the following hierarchy of antimicrobial activity:

Highly Reliable Agents (Use Without Prior Testing)

• Benzylpenicillin: 100% susceptibility across all tested isolates 2
• Amoxicillin-clavulanate: 100% susceptibility 2
• Metronidazole: 100% susceptibility in multiple studies 1, 2
• Cefoxitin: 100% susceptibility 1
• Chloramphenicol: 100% susceptibility 1

Agents Requiring Susceptibility Testing

• Clindamycin: Resistance rates of 9.5-25% reported, making routine testing mandatory 1, 2
• Cefuroxime: Only 93% susceptibility, requiring testing before use 2
• Cefepime: Only 32% of isolates below species-unrelated breakpoints—avoid or test first 2
• Levofloxacin: 56% susceptibility, with quinolone resistance ranging 13-70% across studies 2, 3
• Rifampicin: 98% below locally determined ECOFFs, but testing recommended 2
• Doxycycline: 72% susceptibility, testing advised 2

Critical Clinical Considerations

β-lactamase Production

Despite penicillin resistance observed in 2.4% of isolates, β-lactamase activity was not detected 1. This suggests alternative resistance mechanisms when penicillin resistance occurs, but penicillins remain highly effective overall.

Emerging Resistance Concerns

A 2026 study identified linezolid resistance mediated by the cfr(C) gene in orthopedic infections, particularly following linezolid treatment 4. This represents an important emerging threat, as linezolid was previously considered universally effective. When linezolid fails, tedizolid may serve as an alternative 4.

Geographic and Temporal Variation

Resistance patterns vary significantly by region and time period 1. The Dutch study from 2011 showed different MIC patterns compared to more recent Indian and Swiss data 5, 1, 2, emphasizing the importance of local surveillance.

Treatment Algorithm

For empiric therapy before susceptibility results:

1. First choice: Benzylpenicillin (penicillin G) or amoxicillin-clavulanate
2. Alternative: Metronidazole (particularly for mixed anaerobic infections)
3. Avoid empirically: Cefepime, fluoroquinolones, clindamycin without testing

For targeted therapy after identification:

• Continue penicillin-based therapy if clinically improving
• If penicillin allergy: metronidazole or chloramphenicol
• If prior linezolid exposure: perform susceptibility testing before using oxazolidinones

For polymicrobial infections: Polymicrobial F. magna infections require more surgical interventions and have higher failure rates (36% vs 0% for monomicrobial) 6. Ensure antimicrobial coverage addresses all identified pathogens while maintaining anti-anaerobic activity.

Common Pitfalls

• Assuming all cephalosporins are equivalent: Cefoxitin shows excellent activity while cefepime has poor activity 1, 2
• Using fluoroquinolones empirically: Resistance rates are unacceptably high (13-70%) 3
• Overlooking the need for susceptibility testing with clindamycin: Despite being commonly used for anaerobes, resistance reaches 25-40% in some series 1, 3
• Assuming linezolid is universally effective: Emerging cfr(C)-mediated resistance documented in bone infections 4